Managing Cardiovascular Risk in Type 2 Diabetes

Vanita Aroda, MD; Muthiah Vaduganathan, MD


May 04, 2022

Many patients with type 2 diabetes have multiple risk factors that put them at increased risk for cardiovascular disease.

The latest guidelines recommend not only that patients with diabetes be regularly assessed for increased cardiovascular risk but also that modifiable risk factors be treated.

Dr Vanita Aroda, a leading endocrinologist from Brigham and Women's Hospital in Boston, discusses with her cardiologist colleague Dr Muthiah Vaduganathan the burden of cardiovascular risk in type 2 diabetes and how to tackle it.

The panelists review evidence from multiple trials that have shown the benefit of SGLT2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular events in patients at increased cardiovascular risk.

They examine how to identify which patients are most in need of cardiovascular risk reduction and when to introduce cardioprotective drugs for optimal management.

Finally, Drs Aroda and Vaduganathan discuss multidisciplinary care, shared decision-making, and smart electronic health record systems that can flag upticks in risk as key strategies in cardiovascular risk management.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.